TY - JOUR
T1 - 1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells
AU - Wu, Yanhong
AU - Haugen, James D.
AU - Zinsmeister, Alan R.
AU - Kumar, Rajiv
N1 - Funding Information:
1This work was supported by NIH Grant DK25409. Address correspondence to: Dr. Rajiv Kumar, Mayo Clinic, 200 First St. SW, 911A Guggenheim Bldg., Rochester, MN 55905. Phone: 507-284-0020; Fax: 507-266-4710; E-mail: rkumar@mayo.edu.
PY - 1997/10/29
Y1 - 1997/10/29
N2 - To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.
AB - To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.
UR - http://www.scopus.com/inward/record.url?scp=0031590411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031590411&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1997.7544
DO - 10.1006/bbrc.1997.7544
M3 - Article
C2 - 9367838
AN - SCOPUS:0031590411
SN - 0006-291X
VL - 239
SP - 734
EP - 739
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -